BioDelivery Sciences International Inc.

3.28-0.0600-1.80%Vol 827.85K1Y Perf -21.58%
Apr 20th, 2021 16:00 DELAYED
BID3.24 ASK3.30
Open3.31 Previous Close3.34
Pre-Market- After-Market3.30
 - -  0.02 0.61%
Target Price
7.08 
Analyst Rating
Strong Buy 1.00
Potential %
115.85 
Finscreener Ranking
★★★★★     66.71
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     60.65
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     79.50
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap330.83M 
Earnings Rating
Neutral
Price Range Ratio 52W %
9.96 
Earnings Date
6th May 2021

Today's Price Range

3.233.33

52W Range

3.045.45

5 Year PE Ratio Range

-16.1041.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-5.20%
1 Month
-14.81%
3 Months
-22.09%
6 Months
0.31%
1 Year
-21.58%
3 Years
45.78%
5 Years
-11.11%
10 Years
-11.35%

TickerPriceChg.Chg.%
BDSI3.28-0.0600-1.80
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Financial StrengthValueIndustryS&P 500US Markets
3.00
3.40
0.42
0.72
4.70
Leverage Ratio 2.40
ProfitabilityValueIndustryS&P 500US Markets
84.20
21.10
25.90
-101.40
17.72
RevenueValueIndustryS&P 500US Markets
118.19M
1.17
57.06
44.35
Earnings HistoryEstimateReportedSurprise %
Q04 20200.060.1066.67
Q03 20200.060.0950.00
Q02 20200.040.01-75.00
Q01 20200.010.05400.00
Q04 2019-0.010.06700.00
Q03 2019-0.010.02300.00
Q02 2019-0.060.06200.00
Q01 2019-0.08-0.0537.50
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.07-12.50Negative
6/2021 QR0.04-55.56Negative
12/2021 FY0.28-26.32Negative
12/2022 FY0.53-20.90Negative
Next Report Date6th May 2021
Estimated EPS Next Report0.07
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume827.85K
Shares Outstanding100.86M
Trades Count4.24K
Dollar Volume4.64M
Avg. Volume1.24M
Avg. Weekly Volume1.07M
Avg. Monthly Volume1.09M
Avg. Quarterly Volume1.19M

BioDelivery Sciences International Inc. (NASDAQ: BDSI) stock closed at 3.28 per share at the end of the most recent trading day (a -1.8% change compared to the prior day closing price) with a volume of 827.89K shares and market capitalization of 330.83M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 178 people. BioDelivery Sciences International Inc. CEO is Jeffrey Allen Bailey.

The one-year performance of BioDelivery Sciences International Inc. stock is -21.58%, while year-to-date (YTD) performance is -21.9%. BDSI stock has a five-year performance of -11.11%. Its 52-week range is between 3.04 and 5.45, which gives BDSI stock a 52-week price range ratio of 9.96%

BioDelivery Sciences International Inc. currently has a PE ratio of 14.30, a price-to-book (PB) ratio of 3.19, a price-to-sale (PS) ratio of 2.85, a price to cashflow ratio of 14.40, a PEG ratio of 2.32, a ROA of 11.71%, a ROC of 14.05% and a ROE of 27.92%. The company’s profit margin is 17.72%, its EBITDA margin is 25.90%, and its revenue ttm is $118.19 Million , which makes it $1.17 revenue per share.

Of the last four earnings reports from BioDelivery Sciences International Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.07 for the next earnings report. BioDelivery Sciences International Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for BioDelivery Sciences International Inc. is Strong Buy (1), with a target price of $7.08, which is +115.85% compared to the current price. The earnings rating for BioDelivery Sciences International Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioDelivery Sciences International Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioDelivery Sciences International Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.11, ATR14 : 0.20, CCI20 : -167.87, Chaikin Money Flow : -0.25, MACD : -0.22, Money Flow Index : 27.67, ROC : -14.58, RSI : 38.43, STOCH (14,3) : 7.35, STOCH RSI : 0.00, UO : 27.39, Williams %R : -92.65), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioDelivery Sciences International Inc. in the last 12-months were: Francis E. O'Donnell (Option Excercise at a value of $0), Francis E. O'Donnell (Sold 54 500 shares of value $244 325 ), Herm Cukier (Option Excercise at a value of $0), James Vollins (Option Excercise at a value of $187 692), James Vollins (Sold 63 627 shares of value $281 781 ), Jeffrey Allen Bailey (Option Excercise at a value of $0), Jeffrey Allen Bailey (Sold 10 000 shares of value $43 500 ), Kevin Kotler (Option Excercise at a value of $87 900), Mark A. Sirgo (Option Excercise at a value of $0), Mark A. Sirgo (Sold 800 000 shares of value $3 827 100 ), Mary Theresa Coelho (Option Excercise at a value of $0), Mary Theresa Coelho (Sold 9 922 shares of value $41 306 ), Scott Plesha (Option Excercise at a value of $0), Scott Plesha (Sold 15 000 shares of value $67 800 ), Thomas B. Smith (Option Excercise at a value of $0), Todd C. Davis (Option Excercise at a value of $0), Todd C. Davis (Sold 100 000 shares of value $499 000 ), Vanila Singh (Option Excercise at a value of $0), William Mark Watson (Option Excercise at a value of $0), William Mark Watson (Sold 26 000 shares of value $134 680 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (100.00 %)
9 (100.00 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

BioDelivery Sciences International Inc.

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence.

CEO: Jeffrey Allen Bailey

Telephone: +1 919 582-9050

Address: 4131 ParkLake Avenue, Raleigh 27612, NC, US

Number of employees: 178

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

73%27%

Bearish Bullish

55%45%

Bearish Bullish

58%42%

News

Stocktwits